Shionogi's S-337395 Trial Targets High-Risk RSV Patients
A clinical trial is underway to evaluate the antiviral efficacy of S-337395 in nonhospitalized adults at high risk for severe RSV.
Therapeutic Area
Therapeutic area intelligence for Respiratory Syncytial Virus with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.